Delving into the Latest Updates on ALN-ANG3 with Synapse

Overview

Basic Info

Drug Type

siRNA

Synonyms

ALN ANG3, ALN-ANG

Target

ANGPTL3

Action

inhibitors

Mechanism

ANGPTL3 inhibitors(Angiopoietin like 3 inhibitors)

Therapeutic Areas

Endocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication

Diabetic NephropathiesHyperlipidemias

Inactive Indication-

Originator Organization

Regeneron Pharmaceuticals, Inc.

Active Organization

Alnylam Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.

login

or

view full example data

Boost your research with our RNA technology data.

This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease.
The aim of the study is to see how safe and effective the study drugs are.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug
* How much study drug is in the blood at different times

Start Date09 Jan 2026

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

NCT06452771

/ Active, not recruitingPhase 1

A Phase 1, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, and Pharmacokinetics of ALN-ANG3 in Otherwise Healthy Adult Participants

This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on healthy participants with an elevated level of blood lipids (eg, cholesterol and triglycerides).
The aim of the study is to see how safe and tolerable the study drug is in healthy adult participants.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug
* How much study drug is in the blood at different times
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Start Date27 Jun 2024

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

100 Clinical Results associated with ALN-ANG3

Login to view more data

100 Translational Medicine associated with ALN-ANG3

Login to view more data

100 Patents (Medical) associated with ALN-ANG3

Login to view more data

100 Deals associated with ALN-ANG3

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic Nephropathies	Phase 2	United States	Regeneron Pharmaceuticals, Inc.	09 Jan 2026
Hyperlipidemias	Phase 1	New Zealand	Regeneron Pharmaceuticals, Inc.	27 Jun 2024